Dear Subscriber,
Thank you for your interest in the Center for Biologics Evaluation and Research (CBER) at the FDA. You are receiving this email because you are subscribed to one of our center’s advisory committee public email lists. To ensure you receive timely updates, we’ve decided to combine all our advisory committee email lists into one list called Blood, Vaccines and Other Biologics Advisory Committees Updates.
With your subscription to this email list, you will receive updates on the following advisory committees.
- Allergenic Products Advisory Committee
- Blood Products Advisory Committee
- Cellular, Tissue and Gene Therapies Advisory Committee
- Transmissible Spongiform Encephalopathies Advisory Committee
- Vaccines and Related Biological Products Advisory Committee
You can subscribe to other CBER email lists at fda.gov on the Subscribe to Biologics Mailing Lists page. If you have questions about the email lists, please contact us at CBERWebmaster@xxxxxxxxxxx.
You can unsubscribe from this email list at any time by clicking the unsubscribe link below.
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
